首页|唑来膦酸治疗骨质疏松症出现不良反应的影响因素及列线图预测模型的构建

唑来膦酸治疗骨质疏松症出现不良反应的影响因素及列线图预测模型的构建

扫码查看
目的 分析唑来膦酸治疗骨质疏松症出现不良反应影响因素分析,并构建列线图(Nomogram)预测模型。方法 选取2019年2月至2021年9月于浙江省永康市第六人民医院收治的160例骨质疏松患者为研究对象,根据患者是否出现不良反应分为研究组(有不良反应68例)和对照组(无不良反应92例)。观察2组患者的一般资料,采用受试者工作特征(ROC)曲线分析有统计学意义的连续性变量的预测价值;采用Logistic回归实验分析影响骨质疏松症出现不良反应的相关因素;采用决策曲线分析评估Nomogram模型临床效能。结果 2组患者在年龄、性别等一般资料的比较中差异无统计学意义(P>0。05);与对照组相比,研究组患者使用骨吸收抑制剂以及钙剂占比较少,合并骨折者占比较多,骨钙素和血清钙水平较低(P<0。05);骨钙素和钙的曲线下面积(AUC)分别为0。702和0。653,95%CI分别为(0。625,0。772)、(0。574,0。727),P<0。05;骨吸收抑制剂使用、钙剂使用、骨钙素、血清钙是骨质疏松患者出现不良反应的影响因素(P<0。05);基于危险变量构建Nomogram模型预测骨质疏松症患者出现不良反应的风险一致性指数(C-index)为0。740[95%CI:(0。706,0。774)],且该模型的风险阈值>0。18。结论 骨吸收抑制剂使用、钙剂使用、骨钙素、钙是骨质疏松患者出现不良反应的影响因素,Nomogram模型可以对患者发生不良反应的风险进行较好的评估。
Analysis of affecting factors of adverse reactions in the treatment of osteoporosis with zoledronic acid and construction of nomogram prediction model
Objective To analyze the affecting factors of adverse reactions in the treatment of osteoporosis with zoledronic acid and construct a nomogram prediction model.Methods A total of 160 osteoporosis patients admitted to Yongkang Sixth People's Hospital from February 2019 to September 2021 were enrolled in this study.These patients were categorized into a study group(with adverse reactions,n=68)and a control group(without adverse reactions,n=92).The general characteristics of patients in both groups were observed,and the predictive value of statistically significant continuous variables was evaluated through ROC analysis.Logistic regression analysis was used to identify factors associated with the occurrence of adverse reactions in osteoporosis patients.Additionally,decision curve analysis was utilized to assess the clinical utility of the Nomogram model.Results There was no statistically significant difference between the two groups in terms of general information such as age and gender(P>0.05).Compared to the control group,the study group exhibited less utilization of bone resorption inhibitors and calcium,a higher frequency of combined fractures,and lower levels of osteocalcin and calcium(P<0.05).The A UC values for osteocalcin and calcium were 0.702 and 0.653,respectively,with 95%CI of(0.625,0.772)and(0.574,0.727),indicating their predictive value(P<0.05).The use of bone resorption inhibitors,calcium intake,osteocalcin levels,and calcium levels were identified as the main factors influencing the occurrence of adverse reactions in osteoporosis patients(P<0.05).Furthermore,a Nomogram model constructed based on these risk factors demonstrated a C-index of 0.740[95%CI:(0.706,0.774)]for predicting the risk of adverse reactions in osteoporosis patients.The risk threshold for this model was determined to be>0.18.Conclusion The utilization of bone resorption inhibitors,calcium intake,as well as osteocalcin and calcium levels,are significant factors that contribute to the emergence of adverse effects in patients with osteoporosis.Furthermore,Nomogram modeling offers an enhanced assessment of the risk of adverse effects in these patients

OsteoporosisDrug-related side effects and adverse reactionsRoot cause analysisNomo-grams

徐影、金宏

展开 >

永康市第六人民医院药剂科,浙江永康 321300

骨质疏松 药物相关性副作用和不良反应 影响因素分析 列线图

2024

中国药物与临床
中国医院协会

中国药物与临床

影响因子:0.846
ISSN:1671-2560
年,卷(期):2024.24(5)